Researchers from Joslin Diabetes Center, Boston, and ActiveSite Pharmaceuticals, Inc., San Francisco, announced today that they have demonstrated that a specific inhibitor of the protease plasma kallikrein, ASP-440, developed by ActiveSite Pharmaceuticals, may provide a new therapeutic approach for treatment of diabetic retinopathy, the most common eye-related complication of diabetes. The study, which was partly
Full Post: Protease inhibitor found to aid diabetic retinopathy treatment
Mice from a strain that ordinarily develops systemic lupus erythematosus (SLE), but bred with a deficiency in receptor for the protein Interleukin 21, stayed healthy and exhibited none of the symptoms of the disease, researchers at The Jackson Laboratory and National Institutes of Health report.
SLE is an autoimmune disease, with symptoms of varying severity including include painful or swollen joints, unexplained fever and extreme fatigue. An estimated 2 million Americans - 9 out of 10 of them female - live with SLE.
The primary job of the immune system is to identify and vanquish potentially dangerous infectious pathogens. Autoimmune diseases develop when immune system instead unleashes this potent defense system against the individual’s own tissues, with predictably severe consequences.
Unlike other autoimmune diseases such as Type 1 diabetes, in which the immune response is focused on certain tissues, SLE is a systemic disease in which abnormal antibodies are produced that injure a variety of tissues and organs, including the skin, heart, lungs and kidneys.
The cause of SLE is not well understood, but recent work by a Jackson Laboratory research team led by Professor Derry Roopenian is shedding light on how the disease develops and offers hope for better therapies.
Interleukin 21 (IL21) is produced as part of the response by immune cells known as T cells. The IL21 produced then affects a variety of cells in the normal immune system response. However, IL21 produced in overabundance by individuals susceptible to SLE can cause the defense mechanism to misfire and produce antibodies that attack the individual’s own tissues.
Dr. Roopenian and colleagues at the National Heart, Lung, and Blood Institute and the National Institute of Allergy and Infectious Diseases worked with a mouse model for SLE and demonstrated that IL21 signaling is essential for the SLE-like autoimmune disease to progress. Mice deficient in the cellular receptor for IL21 that were otherwise genetically identical remained healthy and exhibited none of the disease symptoms.
“The findings provide strong clue towards understanding how SLE occurs and a clear indication of the importance of Interleukin 21 signaling in lupus like diseases”, Dr. Roopenian says. “They suggest that interrupting Interleukin 21 signaling events may prove to be an effective therapeutic option for human SLE.”
http://www.jax.org/
--------------------------------------------------------------------------------------------
Related Posts:
Research led by Johns Hopkins Children’s Center scientists has figured out why a respiratory syncytial virus vaccine used in 1966 to inoculate children against the infection instead caused severe respiratory disease and effectively stopped efforts to make a better one. The findings, published online on Dec. 14 in Nature Medicine, could restart work on
Full Post: Researchers solve failed vaccine mystery
Invading pathogens provoke a series of molecular heroics that, when successful, muster an army of antibodies to neutralize the threat. Like with any close-quarter combat, however, an aggressive immune response runs the risk of friendly fire accidents. For the last decade, immunologists have intensively studied mechanisms evolved by the immune system to avoid these accidents
Full Post: Research identifies cell receptor as target for anti-inflammatory immune response
Using a mouse model, researchers have shown that elevated levels of a small protein known as interleukin 7 (IL-7) plays a central role in regulating the production of a type of white blood cell that is required for effective immune responses. This finding helps explain the delayed and incomplete recovery of immune system function after
Full Post: Discovery of new regulatory circuit controlling immune cell production in mice
The Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM) announces the discovery of a new molecular sensor in human cells capable of recognizing infecting viruses and transmitting an alarm signal to the body. The study, directed by the center’s director Giulio Superti-Furga, appears today in the online advanced publication route of the
Full Post: Newly discovered protein acts as virus alarm
The body’s immune system hates strangers. When its security patrol spots a foreign cell, it annihilates it. This is the problem when people with type 1 diabetes undergo human islet cell transplantation. The islet cells from a donor pancreas produce robust amounts of insulin for the recipient — often permitting independence from insulin therapy. However,
Full Post: Scientists trick immune system of mice into believing transplanted islets are its own cells --------------------------------------------------------------------------------------------
